ADMA Biologics Analyst Ratings
ADMA Biologics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/17/2023 | 31.23% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
08/10/2023 | 57.48% | Cantor Fitzgerald | $5 → $6 | Maintains | Overweight |
08/10/2023 | 57.48% | Raymond James | $5 → $6 | Maintains | Strong Buy |
08/10/2023 | 31.23% | HC Wainwright & Co. | $4.5 → $5 | Maintains | Buy |
03/27/2023 | 18.11% | HC Wainwright & Co. | → $4.5 | Reiterates | → Buy |
02/08/2023 | 18.11% | HC Wainwright & Co. | → $4.5 | Reiterates | → Buy |
01/03/2023 | 18.11% | HC Wainwright & Co. | $4 → $4.5 | Maintains | Buy |
11/10/2022 | 57.48% | Mizuho | $5 → $6 | Maintains | Buy |
10/13/2022 | 31.23% | Mizuho | → $5 | Initiates Coverage On | → Buy |
07/25/2022 | 4.99% | HC Wainwright & Co. | $6 → $4 | Maintains | Buy |
11/11/2021 | 31.23% | Raymond James | → $5 | Upgrades | Outperform → Strong Buy |
11/09/2021 | 18.11% | Cantor Fitzgerald | → $4.5 | Initiates Coverage On | → Overweight |
10/26/2021 | 31.23% | Raymond James | $6 → $5 | Maintains | Outperform |
08/12/2021 | 57.48% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
07/06/2021 | 83.73% | HC Wainwright & Co. | $10 → $7 | Maintains | Buy |
03/26/2021 | 57.48% | Raymond James | $7 → $6 | Maintains | Outperform |
01/04/2021 | 188.71% | HC Wainwright & Co. | $12 → $11 | Maintains | Buy |
10/01/2020 | 83.73% | Raymond James | $9 → $7 | Maintains | Outperform |
05/07/2020 | 83.73% | Oppenheimer | $14 → $7 | Maintains | Outperform |
03/16/2020 | 214.96% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
06/04/2019 | 109.97% | Jefferies | → $8 | Initiates Coverage On | → Buy |
04/02/2019 | 319.95% | Oppenheimer | $14 → $16 | Maintains | Outperform |
02/07/2019 | 162.47% | HC Wainwright & Co. | → $10 | Assumes | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/17/2023 | 31.23% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
08/10/2023 | 57.48% | 坎托·菲茨杰拉德 | 5 美元 → 6 美元 | 维护 | 超重 |
08/10/2023 | 57.48% | 雷蒙德·詹姆 | 5 美元 → 6 美元 | 维护 | 强势买入 |
08/10/2023 | 31.23% | HC Wainwright & Co. | 4.5 美元 → 5 美元 | 维护 | 买 |
03/27/2023 | 18.11% | HC Wainwright & Co. | → 4.5 美元 | 重申 | → 购买 |
02/08/2023 | 18.11% | HC Wainwright & Co. | → 4.5 美元 | 重申 | → 购买 |
01/03/2023 | 18.11% | HC Wainwright & Co. | 4 美元 → 4.5 美元 | 维护 | 买 |
2022 年 10 月 11 日 | 57.48% | 瑞穗市 | 5 美元 → 6 美元 | 维护 | 买 |
2022 年 10 月 13 日 | 31.23% | 瑞穗市 | → 5 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 7 月 25 日 | 4.99% | HC Wainwright & Co. | 6 美元 → 4 美元 | 维护 | 买 |
11/11/2021 | 31.23% | 雷蒙德·詹姆 | → 5 美元 | 升级 | 跑赢大盘 → 强势买入 |
2021 年 9 月 11 日 | 18.11% | 坎托·菲茨杰拉德 | → 4.5 美元 | 启动覆盖范围开启 | → 超重 |
10/26/2021 | 31.23% | 雷蒙德·詹姆 | 6 美元 → 5 美元 | 维护 | 跑赢大盘 |
2021 年 12 月 8 日 | 57.48% | HC Wainwright & Co. | 7 美元 → 6 美元 | 维护 | 买 |
2021 年 6 月 7 日 | 83.73% | HC Wainwright & Co. | 10 美元 → 7 美元 | 维护 | 买 |
2021 年 3 月 26 日 | 57.48% | 雷蒙德·詹姆 | 7 美元 → 6 美元 | 维护 | 跑赢大盘 |
01/04/2021 | 188.71% | HC Wainwright & Co. | 12 美元 → 11 美元 | 维护 | 买 |
2020 年 1 月 10 日 | 83.73% | 雷蒙德·詹姆 | 9 美元 → 7 美元 | 维护 | 跑赢大盘 |
05/07/2020 | 83.73% | 奥本海默 | 14 美元 → 7 美元 | 维护 | 跑赢大盘 |
03/16/2020 | 214.96% | HC Wainwright & Co. | 14 美元 → 12 美元 | 维护 | 买 |
06/04/2019 | 109.97% | 杰富瑞集团 | → 8 美元 | 启动覆盖范围开启 | → 购买 |
04/02/2019 | 319.95% | 奥本海默 | 14 美元 → 16 美元 | 维护 | 跑赢大盘 |
02/07/2019 | 162.47% | HC Wainwright & Co. | → 10 美元 | 假设 | → 购买 |
What is the target price for ADMA Biologics (ADMA)?
ADMA Biologics (ADMA) 的目标价格是多少?
The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by HC Wainwright & Co. on November 17, 2023. The analyst firm set a price target for $5.00 expecting ADMA to rise to within 12 months (a possible 31.23% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月17日公布了ADMA Biologics(纳斯达克股票代码:ADMA)的最新目标股价。该分析公司将目标股价定为5.00美元,预计ADMA将在12个月内升至12个月内(可能上涨31.23%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for ADMA Biologics (ADMA)?
分析师对ADMA Biologics (ADMA) 的最新评级是多少?
The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by HC Wainwright & Co., and ADMA Biologics reiterated their buy rating.
HC Wainwright & Co. 提供了ADMA Biologics(纳斯达克股票代码:ADMA)的最新分析师评级,ADMA Biologics重申了其买入评级。
When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?
ADMA Biologics(ADMA)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与ADMA Biologics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。ADMA Biologics的最新评级是在2023年11月17日公布的,因此您应该预计下一个评级将在2024年11月17日左右公布。
Is the Analyst Rating ADMA Biologics (ADMA) correct?
分析师对 ADMA Biologics (ADMA) 的评级是否正确?
While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a reiterated with a price target of $0.00 to $5.00. The current price ADMA Biologics (ADMA) is trading at is $3.81, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但重申了最新的ADMA Biologics(ADMA)评级,目标股价为0.00美元至5.00美元。ADMA Biologics(ADMA)目前的交易价格为3.81美元,在分析师的预测区间内。